Unicharm Corporation

¥1069.5 JPY 1.86T (~USD 12.4B) market cap 2026-02-27

Unicharm Corporation 8113 BUFFETT / MUNGER / KLARMAN SUMMARY

1 SNAPSHOT

Price¥1069.5

Market CapJPY 1.86T (~USD 12.4B)

EVJPY 1.63T

Shares1,498M (post-split)

2 BUSINESS

Unicharm is Asia's largest disposable hygiene products company, operating across baby diapers (Moony, MamyPoko), feminine care (Sofy), adult incontinence (Lifree), and pet care (Deo-Toilet). The company holds #1 market share in baby diapers across Japan, Indonesia, Thailand, Vietnam, and India. ~66% of revenue comes from overseas, with three-fourths of international revenue from Asia (China, Indonesia, Thailand, Vietnam, India). Pet care (~20% revenue) provides recurring, non-cyclical income as Japan's #1 pet toiletries brand. Founded 1961 by Keiichiro Takahara; run by his son Takahisa Takahara since 2001.

Revenue: JPY 945B (FY2025, -4.4% YoY) Organic Growth: 6.1% CAGR (2021-2024)

3 MOAT NARROW

1. Brand recognition in Asia: Moony (premium Japan diapers), MamyPoko (dominant mid-range Asia diapers), Sofy (feminine care) are household names. Parents develop strong loyalty to diaper brands during newborn phase. 2. Distribution infrastructure: 30+ years building multi-tiered distribution across emerging Asian markets, reaching traditional trade channels (small shops, wet markets) in Indonesia, Thailand, Vietnam. Not easily replicated. 3. Scale in Asia: #1 or #2 market share across most Asian hygiene categories provides cost advantages in manufacturing, procurement, and marketing. 4. Aging demographics moat: Adult incontinence (Lifree) benefits from Japan's structural aging trend and healthcare system relationships.

4 MANAGEMENT

CEO: Takahisa Takahara (President & CEO since 2001, son of founder)

Average. Fortress balance sheet (virtually zero net debt, JPY 261B cash) provides safety but depresses ROE. 25 consecutive terms of dividend increases planned (JPY 22/share for 2026). Recently announced JPY 19B share buyback and 65%+ total return ratio target -- a positive shift. But historically too much cash sitting idle. Operating reinvestment has been disciplined (4% of revenue CapEx). India expansion appears well-executed. The massive cash pile suggests either excessive conservatism or limited high-return reinvestment opportunities.

5 ECONOMICS

8.9% (TTM, cyclical low vs 13-15% historical) Op Margin

19.4% ROIC

JPY 97.8B (FY2024) FCF

6 VALUATION

FCF Yield5.3%

DCF RangeJPY 900 - 1,150

Base: FCF JPY 88B (4-yr avg), 5% growth yr 1-5 (recovery + Asia), 4% growth yr 6-10 (maturation), 2% terminal, 8% WACC. Conservative: 3%/2%/1.5% growth, 9% WACC = JPY 900. Optimistic: 7%/5%/2.5% growth, 7.5% WACC = JPY 1,150.

7 MUNGER INVERSION -24.1%

Kill Event	Severity	P()	E[Loss]
China market structural decline (local competition, trading down)	-25%	25%	-6.3%
Prolonged margin compression (raw materials + competition)	-20%	30%	-6.0%
Yen appreciation compresses translated overseas profits	-15%	25%	-3.8%
Asian birth rate decline accelerates (structural baby diaper headwind)	-15%	40%	-6.0%
P&G competitive escalation in Asia	-10%	20%	-2.0%

Tail Risk: A combination of China market collapse, yen appreciation, and margin compression could push the stock to JPY 600-700 (-35% to -40%). However, the fortress balance sheet (JPY 234B net cash), essential nature of hygiene products, and dominant Asian positions make permanent capital loss extremely unlikely. The business would survive and eventually recover; the risk is extended underperformance, not destruction. At JPY 700, normalized FCF yield would be ~8% with massive net cash -- a genuine deep value setup.

8 KLARMAN LENS

Downside Case

In the bear case, China revenue drops 30%, baby diaper volumes decline 5% globally on birth rate trends, and the yen appreciates 10%. Group operating income falls to JPY 80B with 8.5% margins. At 18x compressed earnings, the stock trades at JPY 720 -- a 33% decline from current levels. Even in this scenario, Unicharm remains profitable, the balance sheet is rock-solid, and the company continues generating free cash flow. The floor is real.

Why Market Wrong

The bull case: Unicharm is at a cyclical trough. The China crisis was industry-wide and temporary. Operating margins should normalize to 12-13% as the crisis fades. India is doubling sales every two years and could become a JPY 100B+ revenue market within 5 years. Adult incontinence is a structural growth tailwind in aging Asia. The JPY 19B buyback signals improving capital allocation. At 22x forward (recovery) earnings, the stock could re-rate to JPY 1,400+ within 18 months.

Why Market Right

The market is correctly pricing a business with only 8% ROE, declining operating margins, and a recent earnings collapse. The China crisis may be symptomatic of deeper structural issues: Unicharm's brands may lack the pricing power of a true wide-moat business. P&G earns 22% operating margins on similar products. If Unicharm's normalized margins are 10-12% rather than 13-15%, the fair value is lower than the bulls assume. Declining Asian birth rates are a real headwind for 35% of the business.

Catalysts

For entry: Further China deterioration, earnings miss on FY2026 guidance, yen spike above 130/USD, broad Nikkei correction. For upside (if owned): China feminine care recovery, India market share gains, margin normalization to 13%+, accelerated buybacks, JPY weakening.

9 VERDICT WAIT

B+ T2 Solid

Strong Buy¥750

Buy¥900

Sell¥1400

Unicharm is a solid, well-managed consumer staples business with genuine competitive advantages in Asian hygiene markets. The fortress balance sheet (JPY 234B net cash), strong free cash generation (JPY 88B avg), and dominant Asian market positions provide a real floor of safety. But this is not a wide-moat Buffett business: ROE is below 10%, margins have compressed, and the China crisis exposed brand vulnerability. At JPY 1,069 (28.6x trough earnings, ~21x normalized), the stock is fairly valued but lacks a margin of safety. The DCF base case is JPY 1,020. Wait for a deeper correction to create an entry below JPY 900. Strong buy below JPY 750. The 2026 recovery could drive a re-rating, but the current price already incorporates recovery expectations. Patience. This is a good business that periodically goes on sale -- but it is not on sale today.

🧠 ULTRATHINK Deep Philosophical Analysis

Unicharm: The Quiet Giant of Asian Hygiene

The Core Question

There is something philosophically interesting about a business that exists entirely because human beings need to manage their bodily functions. Diapers, sanitary napkins, incontinence products, cat litter. These are not aspirational purchases. Nobody posts their MamyPoko haul on Instagram. Nobody considers Sofy sanitary napkins a lifestyle statement. And yet, every single day, in every single country where Unicharm operates, hundreds of millions of people reach for these products without thinking. That is the essence of what makes a consumer staples business attractive: the absence of discretion.

Buffett has often said that he likes businesses where the product goes into the consumer and disappears -- Coca-Cola, See's Candies. Unicharm's products don't go into the consumer, but they serve an equally non-negotiable function. A parent of a newborn does not comparison-shop diapers with the same cold rationality they bring to buying a television. They find a brand that works -- that doesn't leak, that doesn't irritate their baby's skin, that fits properly -- and they stick with it. The switching cost isn't financial. It's emotional and practical. The risk of a bad diaper at 3 AM is not worth the savings from a cheaper brand.

This is the foundation of Unicharm's business. Not technology. Not patents. Not network effects. Simple, unglamorous, deeply embedded consumer habit across the most populous continent on earth.

The Moat Meditation

But here is where the romantic narrative meets cold reality. Unicharm's moat is narrower than it appears.

Consider the comparison with Procter & Gamble. P&G earns 22% operating margins on its hygiene products. Unicharm earns 9% on a trailing basis and perhaps 13% normalized. The gap is enormous. It tells you that Unicharm lacks the pricing power, the scale advantages, or the operational efficiency -- or all three -- that a truly wide-moat hygiene business commands.

Part of this is geographic. Unicharm's strongest markets are in developing Asia, where consumers are more price-sensitive and where private-label and local competition is intense. The MamyPoko brand competes on value in Indonesia and Thailand, which is a very different competitive position than Pampers in the United States. Value brands earn value margins.

Part of it is the China experience. In late 2024, a public opinion backlash against sanitary pad safety hit Unicharm's Sofy brand hard enough to require multiple earnings downgrades. This is not what happens to a wide-moat business. True brand power means you can weather a crisis without seeing wholesale orders suspended. Coca-Cola survived contamination scares. Apple survived battery-gate. Unicharm's China franchise, evidently, does not have that level of brand resilience.

The honest assessment: Unicharm has a narrow moat that is wide in specific niches (Moony in Japan, adult incontinence, pet care) and thin in others (China feminine care, Southeast Asian mass-market diapers). The distribution infrastructure across Asia is genuinely difficult to replicate and may be the most durable advantage. But distribution alone, without pricing power, is not enough to earn superior returns.

The Owner's Mindset

Would Buffett own this for 20 years? I think the answer is: he might, at the right price, but he wouldn't consider it a "forever" holding.

The family ownership is reassuring. The Takahara family controls 31% through affiliated vehicles. Takahisa Takahara has been CEO for 24 years. Annual compensation of JPY 400 million is modest. These are not the signs of a management team extracting value from shareholders. The 25 consecutive terms of dividend increases and the recent commitment to 65%+ total shareholder returns suggest a genuine orientation toward shareholders.

But the capital allocation has been merely adequate. The JPY 261 billion cash pile -- 14% of the market cap -- has sat on the balance sheet earning essentially nothing for years. In a country with near-zero interest rates, this is an enormous opportunity cost. Buffett would have either returned this cash to shareholders or found a productive use for it. The recent JPY 19 billion buyback is a welcome signal, but it represents only 7% of the cash hoard. At this rate, it would take over a decade to deploy the excess capital.

The ROIC of 19.4% is impressive and tells you that the operating assets of the business earn good returns. The problem is that the ROE of 8% tells you the company as a whole does not, because of the cash drag. This is a management problem, not a business problem, and it is potentially fixable -- which makes it interesting as a contrarian opportunity.

Risk Inversion

What could permanently impair this business?

Declining Asian birth rates are real but slow-moving and partially offset by rising diaper penetration in India, Africa, and lower-income Asia. The adult incontinence segment directly benefits from aging populations. Pet care is counter-cyclical to birth rates (childless households substitute pets). The demographic risk is more nuanced than it appears at first glance.

China is the genuine risk. Not just the current crisis but the structural uncertainty of operating in a market where government policy, social media mobs, and geopolitical tensions can destroy brand value overnight. If Unicharm's China business were to permanently decline by 50%, the impact would be material but not existential -- perhaps 10-15% of group profits.

The deeper risk is commoditization. If Asian consumers increasingly view diapers and sanitary products as interchangeable commodities, Unicharm's brands lose their premium and margins compress permanently. This is the P&G nightmare scenario: a world where private label captures hygiene products the way it has captured grocery staples in Europe.

The fortress balance sheet means that even in the worst scenarios, Unicharm survives. This is not a business that can go to zero. The question is whether it can generate adequate returns for shareholders -- and at the wrong price, even a surviving business can be a poor investment.

Valuation Philosophy

At JPY 1,069.50 and 28.6x trailing earnings, Unicharm appears expensive. But these are trough earnings. Operating margins have compressed from 15% to 9%. The China crisis is (probably) temporary. A normalization to 12-13% margins would put normalized P/E at 19-21x, which is reasonable for a consumer staples company with Asia growth exposure.

The DCF base case of JPY 1,020 suggests the stock is approximately fairly valued. The 5.3% FCF yield is attractive relative to consumer staples peers. But "approximately fairly valued" is not the same as "a compelling investment." Klarman's margin of safety doctrine demands that you buy at a significant discount to fair value. A 15-30% discount would put the entry zone at JPY 750-900.

The Patient Investor's Path

Unicharm is the kind of stock that rewards patience and punishes impatience.

If you buy today at JPY 1,069, you are paying approximately fair value for a business at cyclical lows. If the 2026 recovery materializes (guided +25% operating income), you might see JPY 1,200-1,400 within 18 months. That is a decent return. But if the recovery disappoints -- if China continues to deteriorate, if margins don't normalize, if the yen strengthens -- you could easily see JPY 875 (the 52-week low) again.

The better approach: place this on the watchlist at JPY 900 and the strong buy list at JPY 750. The next China scare, the next earnings miss, the next broad Nikkei correction will provide the opportunity. In the meantime, study the India opportunity. If Unicharm can replicate in India what it built in Indonesia -- that is the real long-term thesis. India's diaper penetration is still in single digits. The company is doubling sales there every two years. If India becomes a JPY 100 billion revenue market at 15%+ operating margins, the fair value of the business is considerably higher than today's price suggests.

But that is a five-to-ten year story. And five-to-ten year stories are best entered at prices that provide a margin of safety against the inevitable surprises along the way. Unicharm is a good business. It is not yet at a good price. Wait.

Executive Summary

Unicharm is Japan's -- and Asia's -- dominant manufacturer of disposable hygiene products: baby diapers, feminine care products, adult incontinence products, and pet care consumables. It holds #1 market share positions across Japan, Indonesia, Thailand, Vietnam, and India in several categories. The brand portfolio (Moony, MamyPoko, Sofy, Lifree) has genuine consumer recognition across emerging Asia.

However, Unicharm is experiencing a difficult cyclical trough. FY2025 saw a 4.4% revenue decline and a 21.4% drop in core operating income, primarily driven by reputational damage in China's feminine care segment and competitive trading-down across Asia. The stock has declined 34% over three years and 20% over five years. At JPY 1,069.50, it trades at 28.6x trailing earnings on what are arguably trough earnings.

Verdict: WAIT at JPY 1,069. This is a good business at a fair price, but not yet a compellingly cheap one. Accumulate below JPY 900 (22x normalized earnings). Strong buy below JPY 750.

1. Business Overview

What Unicharm Does

Unicharm operates in four segments:

Baby & Child Care (~35% of revenue): Disposable diapers under the Moony (premium, Japan) and MamyPoko (value, Asia) brands. Dominant in Japan, Indonesia, Thailand, Vietnam. Growing rapidly in India.
Feminine Care (~25% of revenue): Sanitary napkins and menstrual products under the Sofy brand. Strong positions across Asia, though recently damaged in China by a reputational crisis.
Health Care / Adult Incontinence (~15% of revenue): Lifree brand adult diapers. Japan's aging demographics make this a secular growth segment.
Pet Care (~20% of revenue): Deo-Toilet cat litter system, pet food. #1 in Japan's pet toiletries market. High recurring revenue.
Other (~5%): Cleaning products, food packaging.

Geographic Mix

Japan: ~34% of revenue
Asia (ex-Japan): ~55% of revenue (China, Indonesia, Thailand, Vietnam, India)
Rest of World: ~11%

The geographic mix is both the opportunity and the risk. Unicharm has built a dominant franchise in the fastest-growing consumer markets in the world. But currency exposure, political risk (particularly China), and the challenges of managing brands across diverse Asian markets create volatility.

The China Crisis (2024-2025)

In late 2024, a public opinion backlash against sanitary pad safety in China severely impacted Unicharm's feminine care sales. Wholesalers and retailers suspended orders. The damage was substantial: core operating income fell 21% for FY2025, and the company issued its first earnings downgrade since 2016.

Management expects recovery in 2026, guiding for 6.8% revenue growth and a 25% rebound in core operating income. The sanitary pad crisis appears to be temporary and industry-wide (not Unicharm-specific), but it exposed the risk of concentrated brand dependence in a politically unpredictable market.

2. Financial Analysis

Income Statement Trends (FY2021-2024, December year-end)

Year	Revenue (¥B)	Operating Income (¥B)	Net Income (¥B)	Op Margin	Net Margin
2024	989.0	134.8	81.8	13.6%	8.3%
2023	941.8	130.7	86.1	13.9%	9.1%
2022	898.0	115.2	67.6	12.8%	7.5%
2021	782.7	118.3	72.7	15.1%	9.3%

FY2025 (ending Dec 2025): Revenue ~JPY 945B (-4.4%), Operating income ~JPY 106B (-21%).

Key observations:

Revenue has grown modestly (CAGR ~6% from 2021-2024) driven by Asia expansion and yen weakness
Operating margins have compressed from 15.1% to 8.9% (TTM), reflecting raw material costs, China crisis, and competitive pressure
Gross margins have narrowed from 40.1% (2021) to 37-39% range, suggesting pricing pressure in competitive Asian markets
ROE has declined from 11.4% to 8.0%, below the 15% Buffett hurdle

Balance Sheet

Year	Total Assets (¥B)	Total Equity (¥B)	Total Debt (¥B)	Cash (¥B)	D/E
2024	1,240	874	26.9	261	0.03
2023	1,134	788	28.6	254	0.04
2022	1,049	709	27.0	217	0.04
2021	988	635	38.3	188	0.06

Key observations:

Fortress balance sheet: virtually zero net debt (¥27B debt vs ¥261B cash)
Equity has grown steadily, reflecting retained earnings
Net cash position of ~¥234B provides massive financial flexibility
Current ratio 2.43x, quick ratio 1.55x -- highly liquid

Cash Flow

Year	Operating CF (¥B)	CapEx (¥B)	Free CF (¥B)	Dividends (¥B)	FCF Yield
2024	137.1	-39.3	97.8	-24.7	5.3%
2023	162.4	-38.4	124.0	-23.1	6.7%
2022	92.2	-33.0	59.3	-22.1	3.2%
2021	105.3	-34.7	70.6	-20.3	3.8%

Key observations:

Strong cash generation: 4-year average FCF of ~¥88B
CapEx is moderate at ~4% of revenue (maintenance + expansion)
Dividend coverage is comfortable (payout ratio ~25-30% of FCF)
FCF yield at current market cap is ~5.3% (attractive for a consumer staples company)

Returns on Capital

ROE: 8.0% (TTM) -- below Buffett's 15% threshold
ROIC (reported): 19.4% -- much higher than ROE due to low debt and high cash balance inflating equity
5-year average ROE: ~10% -- decent but not world-class
Operating margin (TTM): 8.9% -- at cyclical low vs 13-15% historical range

The disconnect between ROE (8%) and ROIC (19.4%) tells an important story. Unicharm earns high returns on its operating assets, but the enormous cash pile (¥261B, 14% of market cap) dilutes equity returns. This suggests either a future for share buybacks/special dividends, or a management team that is overly conservative with capital.

3. Moat Assessment

Rating: NARROW (trending toward WIDE in select markets)

Sources of competitive advantage:

Brand recognition across Asia: Moony is the premium baby diaper in Japan. MamyPoko is the dominant mid-range brand across Southeast Asia. Sofy is a leading feminine care brand. These aren't interchangeable commodity brands -- parents develop loyalty to diaper brands through the critical trial-and-error period with newborns.
Distribution infrastructure: Unicharm has built deep distribution networks across emerging Asian markets over 30+ years. In Indonesia, Thailand, and Vietnam, it has multi-tiered distribution reaching traditional trade channels (small shops, wet markets). This infrastructure is a significant barrier to entry.
Scale in Asia: #1 or #2 market share across most Asian hygiene categories provides cost advantages in manufacturing, raw material procurement, and marketing.
Regulatory moat (aging demographics): In adult incontinence, Unicharm benefits from Japan's aging population and healthcare system relationships. Lifree products are often specified by healthcare providers.

Moat weaknesses:

Products are relatively low-tech; barriers to imitation are moderate
Private label and local competitors can undercut on price (China trading-down trend)
Brand damage can occur quickly (China feminine care crisis)
P&G remains a formidable global competitor with deeper pockets
Commodity raw material exposure (pulp, petroleum-based materials) limits pricing power

Durability: 10-15 years. The Asian distribution networks and brand positions are durable but not indestructible. The moat is widest in Japan (where Unicharm has operated for decades) and narrowest in China (where political risk and intense competition erode advantages).

4. Management Assessment

CEO: Takahisa Takahara (since 2001)

Takahisa Takahara is the son of founder Keiichiro Takahara. He has been President & CEO since 2001 -- over 24 years of tenure. This is a classic Japanese family-controlled business.

Ownership alignment:

Unitec Corporation (family vehicle): 26.58% of shares
Takahara Fund Co., Ltd.: 4.82% of shares
Combined family/affiliated ownership: ~31.4%
Strong skin in the game -- the Takahara family's wealth is primarily in Unicharm stock

Capital allocation: AVERAGE

Conservative financial management (fortress balance sheet, very low debt)
Dividend growth has been steady (25 consecutive terms of increases planned for 2026, JPY 22/share)
Recently announced JPY 19B share repurchase and targeting 65%+ total return ratio
But historically, capital allocation has been suboptimal: too much cash sitting on balance sheet earning near-zero returns
The massive cash pile (¥261B) suggests either excessive conservatism or a lack of high-return reinvestment opportunities

Compensation: ¥400M annual (bonuses = 62.5%), which is modest for a company of this size.

Succession risk: MODERATE. The Takahara family clearly intends to maintain control. Whether the next generation of leadership can navigate the increasingly complex Asian competitive landscape is uncertain.

5. Valuation

Current Multiples

Metric	Value	Historical Range	Assessment
P/E (TTM)	28.6x	20-45x	Fair (on trough earnings)
P/B	2.34x	2-5x	Below historical average
EV/EBITDA	10.9x	10-25x	Near low end
FCF Yield	5.3%	2-5%	Attractive
Dividend Yield	~2.1%	0.5-2%	Above historical range

Normalized Earnings Valuation

Current TTM earnings are depressed (China crisis, competitive pressure). Normalized operating margin should be ~12-13% (vs 8.9% TTM), which on ~¥950B revenue implies:

Normalized operating income: ~¥114-124B
Normalized net income: ~¥75-85B
Normalized EPS: ~¥50-57
Normalized P/E: ~19-21x (current price / normalized earnings)

At 19-21x normalized earnings, Unicharm is fairly valued but not cheap for a business with only 8-10% ROE and single-digit revenue growth.

DCF Analysis

Assumptions:

Owner earnings (FCF): ¥88B (4-year average)
Growth rate years 1-5: 5% (recovery + modest Asia growth)
Growth rate years 6-10: 4% (maturation)
Terminal growth: 2%
Discount rate: 8% (low beta, consumer defensive)

DCF fair value range: ¥900 - ¥1,150 per share

Base case: ¥1,020 -- current price is slightly above base DCF.

Peer Comparison

Company	P/E	Op Margin	ROE	Revenue Growth
Unicharm	28.6x	8.9%	8.0%	-4.4%
Kao Corp	24x	10.5%	9.3%	+3%
P&G	25x	22%	32%	+2%
Kimberly-Clark	18x	16%	80%+	+1%
Hengan (China)	8x	17%	12%	-3%

Unicharm trades at a premium to most global hygiene peers, justified partly by its Asia growth exposure but challenged by below-peer margins and returns.

6. Risk Analysis (Munger Inversion)

What could go wrong?

China structural decline (Severity: -25%, Likelihood: 25%)
- The China feminine care crisis may be symptomatic of deeper issues: intensifying local competition, "trading down" to cheaper brands, regulatory unpredictability.
Prolonged margin compression (Severity: -20%, Likelihood: 30%)
- If operating margins don't recover to 12%+, the stock deserves a lower multiple. Raw material costs + competition could keep margins below 10%.
Yen appreciation (Severity: -15%, Likelihood: 25%)
- 66% of revenue is overseas. A significant yen appreciation would mechanically reduce translated earnings and compress apparent growth.
Asian birth rate decline (Severity: -15%, Likelihood: 40%)
- Japan, China, Thailand, and South Korea all face declining birth rates. Baby diaper volumes are structurally challenged in key markets.
P&G competitive response (Severity: -10%, Likelihood: 20%)
- P&G has the resources to compete aggressively in Asian hygiene markets if it chose to prioritize the region.

Total expected downside: -20.3%

Tail risk: A combination of China market collapse, yen appreciation, and margin compression could push the stock to JPY 600-700 (-35-40%). This would represent a genuine buying opportunity.

7. Investment Thesis

Unicharm is a solid, well-managed consumer staples business with genuine competitive advantages in Asian hygiene markets. The fortress balance sheet (virtually zero net debt, ¥261B cash), strong cash generation (¥88B average FCF), and dominant market positions provide a floor of safety.

However, this is not a Buffett-quality business at the current price. ROE of 8% is below the 15% hurdle. Operating margins have compressed. The China crisis has exposed brand vulnerability. And while the valuation appears reasonable on headline P/E, this is because earnings are at cyclical lows -- on normalized earnings, the stock is fairly valued, not cheap.

The patient investor's path is to wait for a deeper correction. The stock has already declined 34% from its highs, but it hasn't reached the "margin of safety" zone. Key entry triggers:

Accumulate below JPY 900 (~22x normalized earnings, ~6% FCF yield)
Strong buy below JPY 750 (~18x normalized earnings, ~7.5% FCF yield)
These levels would require a further 15-30% decline, which is plausible during the next earnings miss, China scare, or broad market correction.

Recommendation: WAIT

The 2026 earnings recovery (guided +25% operating income) could be a catalyst for re-rating, but the current price already incorporates this expectation. If the recovery disappoints, the stock could revisit JPY 875 (52-week low) or lower, providing a better entry point.

8. Appendix: Data Sources

yfinance: company info, financial statements (FY2021-2024), historical prices (2021-2026), dividends
Unicharm IR website: segment information, FY2025 results, FY2026 guidance
Web research: competitive positioning, China crisis details, management background
Analysis framework: Buffett/Munger/Klarman style value investing principles